[MPP Press release, Link, (CC-BY-NC-ND)] Geneva, 20 January 2016 – The Medicines Patent Pool (MPP) announced its first round of sub-licences for the generic production of Bristol-Myers Squibb’s daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus. Generic companies Cipla, Emcure, Hetero and Natco have signed non-exclusive, royalty free agreements with Bristol-Myers Squibb and the MPP to produce and sell daclatasvir in 112 low- and middle-income countries.
[Electronic Information for Libraries, Link (CC-BY)] The 31st session of WIPO’s Standing Committee on Copyright & Related Rights (SCCR), that met in Geneva from 7 to 11 December 2015, had a full agenda that included discussion on the protection of broadcast organizations, limitations and exceptions for libraries and archives, presentation of a study on museums, and two new proposals by member states.
In a proud moment, the Marrakesh Treaty for persons with print disabilities was ratified by two more countries, bringing the number of ratifications to thirteen. On the downside, there was no agreement to hold regional meetings on libraries and archives.
The United Nations Secretary-General’s High-Level Panel on Access to Medicines is calling for contributions by interested stakeholders that address the misalignment between the rights of inventors, international human rights law, trade rules and public health where it impedes the innovation of and access to health technologies.
In particular the High-Level Panel will consider contributions that promote research, development, innovation and increase access to medicines, vaccines, diagnostics and related health technologies to improve the health and wellbeing of all, as envisaged by Sustainable Development Goal 3, and the 2030 Agenda for Sustainable Development more broadly.
Introduction: GRULAC presents a proposal of discussion on questions regarding the update of copyrights related to ongoing uses of protected intellectual goods in the digital environment in the works of the Standing Committee of Copyright and Related Rights of the World Intellectual Property Organization (SCCR/WIPO).
Standing Committee on Copyright and Related Rights: Thirty-First Session December 7-11, 2015 (Geneva, Switzerland)
Thank you for recognizing me on the issue of promoting limitations and exceptions for educational purposes, potentially within the discussions underway on the needs of libraries.
Organization for Economic Cooperation and Development, Link (CC-BY)
Executive Summary: Education is the key to economic, social and environmental progress, and governments around the world are looking to improve their education systems. The future of education in the 21st century is not simply about reaching more people, but about improving the quality and diversity of educational opportunities. How to best organise and support teaching and learning requires imagination, creativity and innovation.
Open educational resources (OER) are teaching, learning and research materials that make use of tools such as open licensing to permit their free reuse, continuous improvement and repurposing by others for educational purposes. The OER community has grown considerably over the past ten years and the impact of OER on educational systems has become an issue of public policy. This report aims to highlight state of the art developments and practice in OER, but also to serve as a basis for exchanges and discussions that lead to cross-country peer learning on how to improve teaching and learning.
WTO negotiators have agreed to extend a moratorium on “non-violation and situation” complaints under the organisation’s intellectual property rules for an additional two years, forwarding the planned decision to the global trade body’s upcoming ministerial conference for adoption. The news comes as WTO members continue discussing the extension of another moratorium on customs duties on electronic commerce, as well as a decision regarding next steps for an ongoing, related e-commerce work programme. These are also being eyed as outcomes for the ministerial, scheduled for 15-18 December in Nairobi, Kenya.
Joint Statement by 14 Civil Society Groups
Reposted from the Third World Network, Link
Today (6th November), the WTO-TRIPS Council adopted a decision granting Least Developed Countries (LDCs) an exemption from patents and test data protection for pharmaceutical products for a duration of 17 years. With this exemption, LDCs will not be obliged to implement or apply or to enforce patents as well as test data protection for pharmaceutical products until 1 January 2033.
[Reposted from the Third World Network, Link] The United States and the Least Developed Countries (LDCs) at the World Trade Organization have reached agreement ad referendum on a pharmaceutical patent exemption for a duration of 17 years, according to trade diplomats.
With this exemption, the world’s poorest nations will not be obliged “to implement or apply” or “to enforce” patents as well as test data protection for pharmaceutical products until 1 January 2033.
Farida Shaheed, United Nations Special Rapporteur in the field of cultural rights, presented her report on patents and access to culture to the General Assembly. The report’s summary is below, and the full report is available here.
Summary: In the report, the Special Rapporteur addresses the implications of patent policy for the human right to science and culture. She reaffirms the distinction to be made between intellectual property rights and human rights, emphasizing that the right to the protection of the moral and material interests of authors does not necessarily coincide with the prevailing approach to intellectual property law. There is no human right to patent protection. The right to protection of moral and material interests cannot be used to defend patent laws that inadequately respect the right to participate in cultural life, to enjoy the benefits of scientific progress and its applications, to scientific freedoms and he right to food and health and the rights of indigenous peoples and local communities.
Abstract: In April 2014, the United States Trade Representative (USTR) listed India on its Special 301 Priority Watch List, following India’s refusal to grant a patent over the leukemia drug Gleevec and its compulsory licensing of the cancer drug Nexavar. USTR also undertook an out-of-cycle review of India’s intellectual property laws, to determine whether or not to upgrade India to the more serious Priority Foreign Country status, which would potentially trigger retaliation through withdrawal of GSP benefits.
[Cross posted from the TWN Info Service on Intellectual Property Issues, Link] As the World Trade Organization’s intellectual property body begins its session today, there is emerging consensus among the organization’s members that the poorest nations in the world, the least developed countries (LDCs), should not have to apply or enforce pharmaceutical product patents or to implement ‘mailbox’ or exclusive marketing rights for as long as they remain LDCs.
The WTO Trade-Related Aspects of Intellectual Property Rights Agreement (TRIPS) Council is meeting in Geneva on 15-16 October.
However, whether or not these vulnerable nations will clinch their desired demands very much depends on the United States, which remains opposed to LDCs’ requests.